News

Enlarge image

FundingFranceUKGermanyEU

EU fuels rare diseases research

28.01.2013 - The European Commission has kicked off four projects, worth €38m, to improve diagnosis and therapy of rare diseases.

According to the University of Manchester, the European Commission has announced the €38m funding in Barcelona. The money will be channelled into four projects over the next six years: the EURenOmics project aims at identifying genetic and epigenetic roots of rare kidney disorders. It is funded with about €12m and will be coordinated by Heidelberg University Medical Centre, Germany. The Neuromics consortium, which was kicked off last November with funding of almost €12m, will look after biomarkers for rare neurodegenerative and neuromuscular disorders using next generation whole-exome sequencing.  It is led by the University of Tübingen, Germany. Coordination is high on the agenda of the RD-Connect project led by Newcastle University, UK. Funded with around €12m it aims at developing a global infrastructure to share the -omics data of rare disease projects from 70 institutions.  Finally, a communication project called SUPPORT-IRDiRC led by INSERM, France, will receive about €2m.

Orphan diseases have been more and more in the focus of biopharmaceutical companies because they promise fast-track approvals, long market exclusivity and high reimbursement. All projects are part of the International Rare Diseases Research Consortium (IRDiRC). That joint initiative was launched in 2011 to improve diagnosis and treatment of orphan diseases, by identifying the underlying genetic defect through genomics tools. The initiative aims at pooling data and expertise around the world to standardise research. 

Around 80% of the known rare diseases have a genetic component.  The researchers hope to solve the challenge of identifying disease biomarkers by using Next generation sequencing, which allows identification of mutations in a complete set of human genes for several thousands of euros within ten days and subsequent data analysis.  Professor Paul Lasko of McGill University in Montréal, Canada, Chair-Elect of the IRDiRC Executive Committee, explained: "IRDiRC's goal is to reach 200 new rare disease therapies, and diagnoses for all rare diseases, by the year 2020. To this end, it is today launching three major projects which will combine international genetic data with clinical information and data on biomaterials to help interpret the vast amounts of data the genome yields. This will aid scientists in the search for the genetic cause of diseases and help identify new ways to create targeted therapies". Approximately 30 million people across Europe are affected by a rare disease. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/eu-fuels-rare-diseases-research.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOCUTIS (UK)0.08 GBP14.29%
  • SERODUS (N)2.60 NOK4.00%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • DIAMYD MEDICAL -B- (S)4.30 SEK-12.24%

TOP

  • VERONA PHARMA (UK)3.35 GBP26.4%
  • IXICO (UK)34.00 GBP15.3%
  • WILEX (D)1.95 EUR14.7%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-44.9%
  • PROTHENA PLC (IE)31.71 USD-41.1%
  • PLETHORA (UK)2.62 GBP-36.4%

TOP

  • KARO BIO (S)26.00 SEK3614.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)7.00 EUR253.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-85.7%
  • BIOTEST (D)13.24 EUR-85.6%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 08.02.2016